The U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets, marking the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds). The approval was granted to Genzyme Corporation, a Sanofi Company, and was announced on November 18, 2026.
Type 3 Gaucher disease is a rare, inherited condition characterized by the body's inability to properly break down fatty substances known as glucosphingolipids. Unlike Type 1 Gaucher disease, GD3 affects the brain and nervous system, leading to symptoms such as difficulties with balance, coordination, speech, memory, and thinking. Infilbray is a glucosylceramide synthase inhibitor that crosses the blood-brain barrier to reduce the accumulation of these harmful substances in the brain and body.
The approval is supported by data from a randomized, double-blind, multicenter clinical study involving 43 patients aged 12 years and older with GD3. Participants had previously been treated with enzyme replacement therapy and achieved systemic disease stabilization. The study compared patients receiving Infilbray orally once daily against those receiving intravenous enzyme replacement therapy every two weeks for 52 weeks. At the 52-week mark, patients treated with Infilbray demonstrated improvement on a combined measure of neurological assessments compared to the control group.
The FDA granted Infilbray both Orphan Drug designation and Priority Review. Common side effects reported include gastrointestinal symptoms and adverse effects on mood. The drug labeling includes warnings about serious psychiatric risks, including suicidal ideation and behavior. Animal studies identified potential risks such as clouding of vision in younger patients and adverse effects on fetal development during pregnancy.